EFFICACY OF COMBINATION TREATMENT WITH ANTI_IGE PLUS SPECIFIC IMMUNOTHERAPY IN PATIENTS WITH ATOPIC DISEASES
Abstract
Key words: omalizumab, anti Ige antibodies, allergen specific immunotherapy.
About the Authors
N.I. Il'inaRussian Federation
O.M. Kurbacheva
Russian Federation
K.S. Pavlova
Russian Federation
References
1. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус Принт. 1998. 252 с.
2. Bousquet J., Lockey R., Malling H. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998; 53 (44): 1–42.
3. Ebner C., Siemann U., Bohle B. Immunological changes during specific immunotherapy of grass pollen allergy: reduced limphoproliferative responses to allergen and shift from Th2 to Th1 in T-cell clones specific for Ph lp 1, a major grass pollen allergen. Clin. Exp. Allergy. 1997; 27: 1007–1015.
4. Kowalski M., Jutel M. Mechanisms of specific immunotherapy of allergic diseases. Allergy. 1998; 53: 485–492.
5. Busse W., Corren J., Lanier B. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for treatment of severe allergic asthma. J. Allergy. Clin. Immunol. 2001; 108 (2): 184–190.
6. Corren J., Ashby M., Casale T. Omalizumab, a recombinant humanized, anti–IgE antibody, reduces asthma related emergency room visits and hospitalization in patients with allergic asthma. J. Allergy. Clin. Immunol. 2003; 111: 87–90.
7. Soler M., Townley R., Buhi R. et al. The anti–IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 2001; 18 (2): 254–261.
8. Casale T., Bernstein I., Busse W. et al. Use of anti–IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J. Allergy. Clin. Immunol. 1997; 100 (1): 110–121.
9. Chervinsky P., Casale T., Townley R. et al. Omalizumab, an anti–IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann. Allergy. Asthma. Immunol. 2003; 91: 160–167.
10. Lin H., Boesel K., Griffith D. et al. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J. Allergy Clin. Immunol. 2004; 113: 297–302.
11. MacGlashan D., Bochner B., Adelman D. et al. Down-regulation of Fc (epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti–IgE antibody. J. Immunol. 1997; 158: 1438–1445.
12. Vignola A., Humbert M., Bousquet J. et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004; 59: 709–717.
13. Punnonen J., Aversa G., Cocks B.G. Interleukin 13 induces interleukin-4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc. Natl. Acad. Sci. USA. 1993; 90: 30–37.
14. Rolland J., O’Hehir R. Targeting the allergen-specific CD4+ T–cell Strategies for improved allergen immunotherapy. Allergy Clin. Immun. Intern. 2001; 13 (4): 170–177.
15. Akdis M., Verhagen J., Taylor A. et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J. Exp. Med. 2004; 199: 1567–1575.
16. Wachholz P., Durham S. Induction of “blocking” IgG antibodies during immunotherapy. Clin. Exp. Allergy. 2003; 33: 1171–1174.
17. Holgate S., Casale T.B., Wenzel S. et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J. Allergy Clin. Immunol. 2005; 115: 459–465.
18. Beck L., Marcotte G., MacGlashan D. et al. Omalizumab-induced reductions in mast cell Fcepsilon RI expression and function. J. Allergy Clin. Immunol. 2004; 114: 527–530.
19. Abramson M., Puy R., Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy. 1999; 54: 1022–1041.
20. Durham S., Varney V., Gaga M. Grass pollens immunotherapy remains effective 3 years after discontinuation: a double blind, placebo controlled withdrawal study. Clin. Exp. Allergy. 1998; 88: 43–53.
21. Курбачева О.М. Клинические, патогенетические и экономические аспекты применения аллерген–специфической иммунотерапии. Дис. … докт. мед. наук. М. 2007. 195 с.
22. Passalacqua G., Canonica G.W. Long-lasting clinical efficacy of allergen specific immunotherapy. Allergy. 2002; 57: 275–276.
23. Dolz I., Martinez-Cocera C., Bartolome J. et al. A double-blind, placebo-controlled study of immunotherapy with grass pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy. 1996; 51 (7): 489–500.
24. Ortolani C., Pastorello E., Moss R. Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J. Allergy Clin. Immunol. 1984; 73: 283–290.
25. Zenner H., Baumgarten C., Rasp G. et al. Short-term immunotherapy: a prospective, randomized, double blind, placebo controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. J. Allergy Clin. Immunol. 1997; 100: 23–29.
26. Passalacqua G., Guerra L., Pasquali M. et al. Efficacy and safety of sublingual immunotherapy. Ann. Allergy Asthma. Immunol. 2004; 93: 3–12.
27. Гущин И.С., Курбачева О.М. Аллерген–специфическая иммунотерапия атопических заболеваний. Пособие для врачей. М. 2002. 32 с.
28. Nelson B., Dupont L., Reid M. Prospective survey of local and systematic reactions to immunotherapy with pollen extracts. Ann. Allergy. 1986; 56: 331–334.
29. Greineder D. Risk management in allergen immunotherapy. J. Allergy. Clin. Immunol. 1996; 98 (3): 330–334.
30. Hejjaoui J., Ferrando R., Dhivert H. et al. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J. Allergy. Clin. Immunol. 1992; 89: 925–933.
31. Stewart G., Lockey R. Systemic reactions from allergen immunotherapy. J. Allergy. Clin. Immunol. 1992; 90: 567–578.
32. Nielsen L., Johnsen C., Mosbech H. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J. Allergy. Clin. Immunol. 1996; 97 (6): 1207–1213.
33. Businco L., Zannino L., Cantani A. et al. Systemic reactions to specific immunotherapy in children with respiratory allergy: a prospective study. Pediatric. Allergy. Immunol. 1995; 6: 44–47.
34. Астафьева Н.Г. Роль мотивации пациента в проведении специфической вакцинации аллергии. Пульмонология. 2004; 1: 99–104.
35. Kueher J., Brauburger J., Sielen S. et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J. Allergy. Clin. Immunol. 2002; 109: 274–280.
36. Rolinck-Werninghaus C., Hamelmann E., Keil T. et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy. 2004; 59: 973–979.
37. Casale T., Busse W., Kline J. et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed induced seasonal allergic rhinitis. J. Allergy. Clin. Immunol. 2006; 117: 134–140.
38. Klunker S., Saggar L., Seyfert–Margolis V. et al. Combination treatment with omalizumab and rush immunotherapy for ragweed induced allergic rhinitis: inhibition of IgE–facilitated allergen binding. J. Allergy. Clin. Immunol. 2007; 120: 688–695.
39. Parks K., Casale T. Anti-immunoglobulin E monoclonal antibody administred with immunotherapy. Allergy. Asthma. Proc. 2006; 2 (Suppl. 1): 33–36.
40. Schulze J., Rose M., Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy. 2007; 62: 963–964.
41. Порошина Ю.А., Полсачева О.В., Передкова Е.В. Ускоренный метод специфической иммунотерапии поллинозов. Методические рекомендации. М. 1988. 12 с.
Review
For citations:
Il'ina N., Kurbacheva O., Pavlova K. EFFICACY OF COMBINATION TREATMENT WITH ANTI_IGE PLUS SPECIFIC IMMUNOTHERAPY IN PATIENTS WITH ATOPIC DISEASES. Current Pediatrics. 2008;7(3):44-51.
Email this article 
